NMT gets back on track with STARFlex heart implant
This article was originally published in Clinica
Following a setback with the US FDA last year, Boston, Massachusetts implant specialist NMT Medical is renewing efforts to gain market approval for its STARFlex implant for closing a heart defect that can increase the risk of stroke.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.